Open AccessThe Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
Author(s) -
Kira R. Brice,
Maria Tzefos
Publication year - 2011
Publication title -
clinical medicine insights endocrinology and diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.113
H-Index - 2
ISSN - 1179-5514
DOI - 10.4137/cmed.s4086
Subject(s) - liraglutide , exenatide , medicine , type 2 diabetes mellitus , type 2 diabetes , clinical trial , pharmacology , glycemic , glucagon like peptide 1 receptor , adverse effect , diabetes mellitus , placebo , endocrinology , agonist , alternative medicine , receptor , pathology
To review the efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists to determine their role in type 2 diabetes mellitus (T2DM).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom